Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Headache ; 63(3): 455-458, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36905157

RESUMO

BACKGROUND: Ictal epileptic headache (IEH) is caused by a focal epileptic seizure. The diagnosis can be challenging when the headache is isolated without any other symptoms. CASE REPORT: A 16-year-old girl presented with a 5-year history of bilateral frontotemporal headaches with severe intensity lasting for 1-3 min. Past medical, physical, and developmental histories were unremarkable. Head magnetic resonance imaging showed right hippocampal sclerosis. The diagnosis of pure IEH was confirmed by video-electroencephalographic monitoring. The onset and cessation of frontal headache correlated with a right temporal discharge. The patient was diagnosed with right mesial temporal lobe epilepsy. Two years later, her seizures increased despite antiseizure medications. A right anterior temporal lobectomy was performed. The patient remained seizure-free and headache-free for 10 years. CONCLUSION: IEH should be considered in the differential diagnosis of brief and isolated headache, even if the headache is diffuse or contralateral to the epileptogenic focus.


Assuntos
Epilepsia do Lobo Temporal , Epilepsia , Humanos , Feminino , Adolescente , Epilepsia/diagnóstico , Cefaleia/etiologia , Cefaleia/complicações , Eletroencefalografia/efeitos adversos , Epilepsia do Lobo Temporal/diagnóstico , Epilepsia do Lobo Temporal/diagnóstico por imagem , Convulsões , Imageamento por Ressonância Magnética
2.
Eur J Pain ; 25(2): 466-472, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33078485

RESUMO

INTRODUCTION: Pain is underdiagnosed and undertreated in patients with Alzheimer's disease (AD). Pain management is of major importance in this population to limit behavioural and functional consequences. Our study aimed to assess the capacity of AD patients to represent pain using a questionnaire exploring daily painful situations and to determine the most appropriate pain scale assessment. METHODS: Twenty-eight patients with mild AD, 21 with moderate AD and 28 matched controls underwent the Situation Pain Questionnaire (SP-Q) and assessed imaginary pain with four pain scales. Two scores were compared between the three groups: the P(A) discrimination score and the response bias ß score. P(A) reflects the degree of discrimination between high-pain and low-pain events, whereas the ß score means the degree to which situations are considered as painful. RESULTS: Our results showed that AD patients hardly discriminated the high- from low-pain events. Compared to controls, the mean P(A) score was significantly lower for Mild AD (p < 0.03) and Moderate AD (p < 0.004). In addition, the ß score indicated that the response bias is higher for AD patients (p < 0.01) in that they overestimated the level of pain. CONCLUSION: The present results suggest that patients with Mild and Moderate AD are able to recognize and assess an imagined painful situation even though their pain tolerance is lower than that of controls. The pain scales used should be chosen according to the cognitive, sensorial and personal profiles of the patients. SIGNIFICANCE: The present research is significant because it examines how patients with Alzheimer's disease understand and assess painful situations. Cognitive impairments can modify this ability. Pain is a sensory and subjective experience and to define its feeling can help us in our clinical practice.


Assuntos
Doença de Alzheimer , Disfunção Cognitiva , Doença de Alzheimer/complicações , Humanos , Dor , Medição da Dor , Limiar da Dor
3.
J Neurol Sci ; 345(1-2): 224-7, 2014 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-25115501

RESUMO

BACKGROUND: Patients with peripheral neuropathy and anti-MAG monoclonal IgM may respond to Rituximab, a humanized monoclonal anti-CD20 antibody. METHODS: We report on three patients with peripheral neuropathy and anti-MAG monoclonal IgM who deteriorated under Rituximab and reviewed seven previously published cases. RESULTS: Worsening was acute and severe, and occurred during the treatment period. All the patients improved after deterioration but at final evaluation only one was improved comparatively to baseline, five were worsened and four were stabilized. Deterioration was not clearly associated with an increase of the anti-MAG antibody titer. Two patients received Rituximab prior or after the course which induced worsening without adverse reaction. CONCLUSION: Although rare, acute worsening of the neuropathy can occur after Rituximab. The deterioration is however reversible within some weeks to several months.


Assuntos
Anticorpos Monoclonais Murinos/efeitos adversos , Imunoglobulina M/sangue , Fatores Imunológicos/efeitos adversos , Glicoproteína Associada a Mielina/imunologia , Polineuropatias/tratamento farmacológico , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Rituximab
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...